Tyrphostin AG 879

Tyrphostin AG 879 (AG 879) is a tyrosine kinase inhibitor that inhibits TrKA phosphorylation (IC50 of 10 μM), but not TrKB and TrKC. Tyrphostin AG 879 is also a selective ErbB2 tyrosine kinase inhibitor with an IC50 of 1 μM, and has at least 500-fold higher selectivity to ErbB2 than EGFR. Tyrphostin AG 879 has anticancer activity[1][2][3].

Product Specifications

CAS Number

[148741-30-4]

Product Name Alternative

AG 879

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; EGFR; Trk Receptor

Type

Reference compound

Related Pathways

Apoptosis; JAK/STAT Signaling; Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Tyrphostin-AG-879.html

Purity

99.26

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

S=C(N)/C(C#N)=C/C1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1

Molecular Formula

C18H24N2OS

Molecular Weight

316.46

Precautions

H302, H315, H319, H335

References & Citations

[1]Zhou Y, et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. Cancer Res. 2006 Jan 1;66 (1) :404-11.|[2]Levitzki A, et al. Tyrosine kinase inhibition: an approach to drug development. Science. 1995 Mar 24;267 (5205) :1782-8.